Gemtuzumab Ozogamicin (Mylotarg®) in Children with Refractory or Relapsed Acute Myeloid Leukemia

Autor:	Dirk Reinhardt, Christian M. Zwaan, G. J. L. Kaspers, Ursula Creutzig, Michael Dworzak, Heribert Jürgens, S Diekamp, Gudrun Fleischhack, C Corbacioglu
Rok vydání:	2004
Předmět:	Cancer Research Gemtuzumab ozogamicin business.industry CD33 Myeloid leukemia Hematology Pharmacology Immunoconjugate chemistry.chemical_compound Oncology Refractory chemistry Calicheamicin medicine Cancer research business medicine.drug
Zdroj:	Oncology Research and Treatment. 27:269-272
ISSN:	2296-5262 2296-5270
DOI:	10.1159/000075606
Popis:	Background: Gemtuzumab ozogamicin (GO) is an immunoconjugate consisting of the CD33 antibody and calicheamicin, a potent cytotoxic agent. Developed for targeted treatment of CD33-po
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d5ddb89414135dfeb95caa1e89e1491b https://doi.org/10.1159/000075606 Zobrazit plný text záznamu